Shenzhen Hepalink Pharmaceutical Group Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Yu Shan
Chief executive officer
CN¥2.6m
Total compensation
| CEO salary percentage | 49.5% |
| CEO tenure | 26.7yrs |
| CEO ownership | n/a |
| Management average tenure | 2.5yrs |
| Board average tenure | 13.8yrs |
Recent management updates
Recent updates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Business Is Trailing The Industry But Its Shares Aren't
Dec 06
Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Oct 07Some Shareholders Feeling Restless Over Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) P/S Ratio
Aug 22Here's Why Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Can Afford Some Debt
Jun 12Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) 26% Price Boost Is Out Of Tune With Revenues
May 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CN¥146m |
| Jun 30 2024 | n/a | n/a | -CN¥243m |
| Mar 31 2024 | n/a | n/a | -CN¥695m |
| Dec 31 2023 | CN¥3m | CN¥1m | -CN¥783m |
| Sep 30 2023 | n/a | n/a | CN¥218m |
| Jun 30 2023 | n/a | n/a | CN¥340m |
| Mar 31 2023 | n/a | n/a | CN¥559m |
| Jan 01 2023 | n/a | n/a | CN¥727m |
| Sep 30 2022 | n/a | n/a | CN¥432m |
| Jun 30 2022 | n/a | n/a | CN¥414m |
| Mar 31 2022 | n/a | n/a | CN¥332m |
| Jan 01 2022 | n/a | n/a | CN¥241m |
| Sep 30 2021 | n/a | n/a | CN¥777m |
| Jun 30 2021 | n/a | n/a | CN¥781m |
| Mar 31 2021 | n/a | n/a | CN¥912m |
| Dec 31 2020 | CN¥5m | CN¥2m | CN¥1b |
| Sep 30 2020 | n/a | n/a | CN¥1b |
| Jun 30 2020 | n/a | n/a | CN¥1b |
| Mar 31 2020 | n/a | n/a | CN¥808m |
| Dec 31 2019 | CN¥2m | CN¥2m | CN¥1b |
Compensation vs Market: Yu's total compensation ($USD362.68K) is above average for companies of similar size in the CN market ($USD163.77K).
Compensation vs Earnings: Yu's compensation has increased whilst the company is unprofitable.
CEO
Yu Shan (64 yo)
26.7yrs
Tenure
CN¥2,647,000
Compensation
Mr. Yu Shan co-founded Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in April 1998 and has been its General Manager since April 21, 1998 and serves as its Group Vice President. From August 1982 to Febru...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26.7yrs | CN¥2.98m | no data | |
| Co-Founder | 26.7yrs | CN¥2.65m | no data | |
| VP of Finance | 1.3yrs | CN¥992.60k | no data | |
| VP, Deputy GM & Director | no data | CN¥2.45m | no data | |
| Company Secretary | 3.2yrs | CN¥1.67m | no data | |
| Chief Business Officer | no data | no data | no data | |
| Senior Vice President of Global Supply Chain | 1.8yrs | no data | no data |
2.5yrs
Average Tenure
60yo
Average Age
Experienced Management: 002399's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 26.7yrs | CN¥2.98m | no data | |
| Co-Founder | 26.7yrs | CN¥2.65m | no data | |
| VP, Deputy GM & Director | 26.7yrs | CN¥2.45m | no data | |
| Supervisor | 17yrs | no data | no data | |
| Employee Supervisor | 17yrs | no data | no data | |
| Chairman of Supervisory Board | 10.6yrs | no data | no data | |
| Independent Non-Executive Director | 5yrs | CN¥100.00k | no data | |
| Chairman of Hepalink’s Scientific Advisory Board | no data | no data | no data | |
| Member of Hepalink’s Scientific Advisory Board | no data | no data | no data | |
| Director | 1.6yrs | CN¥3.49m | no data | |
| Independent Non-Executive Director | 1.6yrs | CN¥58.00k | no data | |
| Independent Non-Executive Director | 1.6yrs | CN¥58.00k | no data |
13.8yrs
Average Tenure
56.5yo
Average Age
Experienced Board: 002399's board of directors are seasoned and experienced ( 13.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 07:26 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lei Tian | AJ Securities Co., Ltd |
| Peng Yan | Changjiang Securities Co. LTD. |
| Diandian Li | China Merchants Securities Co. Ltd. |